INVENTIONS FOR LICENSE
MCL 1778.0: Dopamine D4 Receptor-Selective Antagonists as Treatment for Attention Deficit-Hyperactivity Disorder
Ross Baldessarini, M.D., et al.
- Treatment of ADHD
Background and Description
The invention is based on the finding that motor hyperactivity can be dose-dependently reversed by receptor-specific antagonists of a key neuronal receptor. The invention therefore comprises compounds for treating motor hyperactivity disorders such as attention deficit-hyperactivity disorder (ADHD), and methods of using such compounds in treatment of these diseases.
Potential Commercial Uses
The compounds and methods of the invention will be useful in treating ADHD and related disorders. These compounds are expected to be superior to conventional therapies using psychostimulants in that they do not stimulate dopamine release or block its inactivation by reuptake or transport.
Publication and Patent Status
McLean Hospital is the owner of issued U.S. patent number 6,747,029 claiming this invention. (USPTO # 6,747,029)
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax